This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovasculardisease.
BackgroundRING finger protein 213 (RNF213) p.R4810K is an established risk factor for moyamoya disease and intracranial artery stenosis in East Asian people. Recent evidence suggests its potential association with extracranial cardiovasculardiseases, including pulmonary hypertension. All patients had cerebrovasculardiseases.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovasculardisease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Objective We aimed to summarize the association between gestational diabetes mellitus (GDM) and its intergenerational cardiovasculardiseases (CVDs) impacts in both mothers and offspring post-delivery in existing literature.
Background and aims In the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovasculardiseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. 3.95, p = 0.003). 3.95, p = 0.003). vs. 45.8%; 17.6% vs. 13.9%, p = 0.001).
Methods This narrative review examines the contemporary literature assessing intermediate- and long-term event rates in patients with established CV disease treated with statins. Recurrent stroke occurs in up to 19% of patients seven years after a first cerebrovascular event.
Early identification allows for timely initiation of guideline-directed medical therapy for secondary prevention of cardiovasculardisease, cerebrovasculardisease, and limb events.
Background and aims Epidemiology of atherosclerotic cardiovasculardisease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL).
Six multimorbidity patterns were identified, including 4 specific patterns: (1) pattern 1, cerebrovascular cluster (histories of cerebrovasculardisease and hypertension); (2) pattern 2, traditional cardiovasculardisease risk factors cluster (histories of hyperlipidemia, obesity, anddiabetes, and family history of cardiovasculardisease and smoking); (..)
Hypertension is the primary modifiable risk factor for cardiovascular, renal, and cerebrovasculardiseases and is considered the main contributing factor to morbidity and mortality worldwide.
Atherosclerotic cardiovasculardisease (ASCVD) was defined as history/presence of coronary, peripheral, or cerebrovasculardisease. We estimated MAVE rates and cumulative incidence, overall and by ASCVD. Over half (52%) of the cohort met the ASCVD criteria.
Introduction:Lipoprotein(a) [Lp(a)] is a known risk factor for cardiovasculardisease; however, its association with cerebrovasculardisease is not as well established.Methods:Data from HCHS/SOL, a population-based cohort of Hispanics/Latinos, was utilized.
Introduction:Cardiovascular comorbidities are highly prevalent in patients who suffer from cerebrovasculardisease. Peak oxygen uptake (VO2peak) is a well-established, independent predictor of cardiovascular health and premature mortality. Dyslipidemia also contributes significantly to cardiovasculardisease risk.
Introduction:Despite significant efforts to increase public awareness of cerebrovasculardisease, the incidence of stroke and transient ischemic attack (TIA) in young adults has remained elevated, representing a major public health concern. Stroke, Volume 55, Issue Suppl_1 , Page ATP271-ATP271, February 1, 2024.
According to WHO , cardiovasculardiseases are the leading cause of death worldwide – it is estimated that they are the cause of 17.9 Cardiovasculardiseases are a group of diseases of the heart and blood vessels. They include coronary artery disease, cerebrovasculardisease, and rheumatic heart disease.
Objectives We aimed to investigate the associations between air pollutants and the risk of admission and multiple readmission events for cardiovasculardisease (CVD). Methods A total of 285 009 participants free of CVD at baseline from the UK Biobank were included in this analysis.
Despite these well-documented risks, the National Survey on Drug Use and Health reports that illicit stimulant use is increasing.Research Question:How have mortality rates changed over time when cardiovasculardisease (CVD) is the underlying cause of death and illicit stimulant use is a contributing factor?Aims:To
Annual costs to the US health care system were estimated by multiplying the mean annual number of events by the mean total cost per discharge.RESULTS:The annual mean number of hospital discharges among CVD events was the highest for heart failure (1 087 000 per year) and cerebrovasculardisease (800 600 per year).
Cardiovasculardiseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, cerebrovasculardisease (e.g., stroke), peripheral arterial disease, congenital heart anomalies, deep vein thrombosis, and pulmonary embolism.
ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovasculardiseases, cerebrovasculardiseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions.
History of Cardiovasculardisease (all studies): Especially any history of heart failure or structural cardiac disease, including valvular 4. Negative predictors included dementia, pacemaker, coronary revascularization, and cerebrovasculardisease. Age greater than 65 (Sarasin and STePS) 3. 16) Linzer M.
Elevated cardiovascular mortality risks were observed across all subgroups, including diseases of the heart (IRR 1.79, 95% CI 1.751.82), cerebrovasculardiseases (IRR 1.52, 95% CI 1.451.59), and other cardiovasculardiseases (IRR 1.78, 95% CI 1.671.90).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
73 
Let's personalize your content